📣 VC round data is live. Check it out!
- Public Comps
- 3D Medicines
3D Medicines Valuation Multiples
Discover revenue and EBITDA valuation multiples for 3D Medicines and similar public comparables like Cantargia, Dimerix, Eurofins-Cerep, Laboratorios Richmond and more.
3D Medicines Overview
About 3D Medicines
3D Medicines Inc is a commercial-stage biopharmaceutical company engaged in the research and development of oncology therapies for cancer patients, especially those who require long-term care. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life. It generates all of its revenue from China.
Founded
2018
HQ

Employees
191
Website
Financials (FY)
EV
$52M
Valuation Multiples
Start free trial3D Medicines Financials
3D Medicines reported last fiscal year revenue of $66M and negative EBITDA of ($24M).
In the same fiscal year, 3D Medicines generated $60M in gross profit, ($24M) in EBITDA losses, and had net loss of ($27M).
3D Medicines P&L
In the most recent fiscal year, 3D Medicines reported revenue of $66M and EBITDA of ($24M).
3D Medicines is unprofitable as of last fiscal year, with gross margin of 92%, EBITDA margin of (37%), and net margin of (41%).
Financial data powered by Morningstar, Inc.
3D Medicines Stock Performance
3D Medicines has current market cap of $94M, and enterprise value of $52M.
3D Medicines' stock price is $0.38.
3D Medicines has an EPS (earnings per share) of $-0.11.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $52M | $94M | 0.0% | — | — | — | $-0.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free Trial3D Medicines Valuation Multiples
3D Medicines trades at 0.8x EV/Revenue multiple, and (2.2x) EV/EBITDA.
3D Medicines Financial Valuation Multiples
As of May 10, 2026, 3D Medicines has market cap of $94M and EV of $52M.
3D Medicines has a P/E ratio of (3.5x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified 3D Medicines Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


3D Medicines Margins & Growth Rates
In the most recent fiscal year, 3D Medicines reported gross margin of 92%, EBITDA margin of (37%), and net margin of (41%).
3D Medicines Margins
3D Medicines Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
3D Medicines Operational KPIs
3D Medicines' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.4M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
3D Medicines Competitors
3D Medicines competitors include Cantargia, Dimerix, Eurofins-Cerep, Laboratorios Richmond, Agronomics, Rein Therapeutics, aTyr Pharma, Dongkoo Bio&Pharma Co, Rani Therapeutics and Coya Therapeutics.
Most 3D Medicines public comparables operate across Biopharmaceuticals, Diagnostics & Genomics, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 2.4x | 3.7x | 5.1x | 21.5x | |||
| 16.2x | 13.1x | (3.2x) | (3.8x) | |||
| 1.4x | — | 9.1x | — | |||
| 2.9x | — | 10.8x | — | |||
| (5.7x) | — | (2.6x) | — | |||
| — | — | (4.2x) | — | |||
| 137.5x | 213.6x | (0.3x) | (0.4x) | |||
| 0.9x | — | 3.1x | — | |||
This data is available for Pro users. Sign up to see all 3D Medicines competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout 3D Medicines
| When was 3D Medicines founded? | 3D Medicines was founded in 2018. |
| Where is 3D Medicines headquartered? | 3D Medicines is headquartered in China. |
| How many employees does 3D Medicines have? | As of today, 3D Medicines has over 191 employees. |
| Is 3D Medicines publicly listed? | Yes, 3D Medicines is a public company listed on HKEX. |
| What is the stock symbol of 3D Medicines? | 3D Medicines trades under 01244 ticker. |
| When did 3D Medicines go public? | 3D Medicines went public in 2022. |
| Who are competitors of 3D Medicines? | 3D Medicines main competitors include Cantargia, Dimerix, Eurofins-Cerep, Laboratorios Richmond, Agronomics, Rein Therapeutics, aTyr Pharma, Dongkoo Bio&Pharma Co, Rani Therapeutics, Coya Therapeutics. |
| What is the current market cap of 3D Medicines? | 3D Medicines' current market cap is $94M. |
| What is the current revenue of 3D Medicines? | 3D Medicines' last fiscal year revenue is $66M. |
| What is the current EV/Revenue multiple of 3D Medicines? | Current revenue multiple of 3D Medicines is 0.8x. |
| Is 3D Medicines profitable? | No, 3D Medicines is not profitable. |
| How many companies 3D Medicines has acquired to date? | 3D Medicines hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies 3D Medicines has invested to date? | 3D Medicines hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to 3D Medicines
Lists including 3D Medicines
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.